Effect of Probenecid on Synovial Fluid ATP Levels in CPPD
Status:
Completed
Trial end date:
2021-04-08
Target enrollment:
Participant gender:
Summary
This study will investigate the hypothesis that probenecid, a medication currently used for
gout, reduces levels of ATP in the joint fluid of patients with calcium pyrophosphate
deposition disease (CPPD), another common type of crystal-related arthritis. There is good
evidence that CPPD results from an excess of ATP in joints. The investigators will measure
levels of ATP in joint fluid before and after 5 days of treatment with probenecid. This study
will serve to rationalize larger studies of probenecid in CPPD.